Brokerages Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) PT at $4.93

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) has earned an average recommendation of "Hold" from the seven brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $4.93.

SGMO has been the topic of several recent analyst reports. Royal Bank of Canada reissued a "sector perform" rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research report on Thursday, March 14th. StockNews.com began coverage on shares of Sangamo Therapeutics in a research note on Tuesday, February 13th. They set a "sell" rating for the company. Finally, HC Wainwright restated a "buy" rating and set a $5.00 price target (up previously from $3.00) on shares of Sangamo Therapeutics in a research note on Tuesday, March 19th.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC grew its stake in Sangamo Therapeutics by 3.7% in the 3rd quarter. Acadian Asset Management LLC now owns 2,927,769 shares of the biopharmaceutical company's stock valued at $1,753,000 after buying an additional 105,789 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Sangamo Therapeutics by 16.8% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 613,724 shares of the biopharmaceutical company's stock valued at $798,000 after purchasing an additional 88,444 shares during the period. Vanguard Personalized Indexing Management LLC bought a new position in Sangamo Therapeutics in the 3rd quarter valued at $26,000. Golden State Equity Partners boosted its holdings in Sangamo Therapeutics by 22.5% in the 3rd quarter. Golden State Equity Partners now owns 166,265 shares of the biopharmaceutical company's stock valued at $100,000 after purchasing an additional 30,500 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in Sangamo Therapeutics by 103.9% in the 4th quarter. SG Americas Securities LLC now owns 180,544 shares of the biopharmaceutical company's stock valued at $98,000 after purchasing an additional 92,002 shares during the period. 56.93% of the stock is currently owned by hedge funds and other institutional investors.

Sangamo Therapeutics Price Performance

Shares of Sangamo Therapeutics stock traded up $0.05 during mid-day trading on Friday, hitting $0.67. 1,264,612 shares of the stock were exchanged, compared to its average volume of 2,299,029. Sangamo Therapeutics has a 12 month low of $0.29 and a 12 month high of $1.82. The company has a 50-day simple moving average of $0.79 and a 200 day simple moving average of $0.62.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.